Bristol Myers Squibb and Johnson & Johnson said on Friday they would stop a late-stage trial of their experimental blood clot drug in heart attack patients, after an independent review found the study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback